Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation phenotype BEFREE Patients with p53 gene mutations showed chemoresistance (progressive disease of 42.9%, P = .0339) and a relatively poor prognosis after chemotherapy (P = .1391). 21527506 2011
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE Regarding the efficacy of anti-EGFR therapy, the patient with an I326V mutation had progressive disease (+115%) despite no genetic alterations detected in the EGFR pathway that could drive resistance, suggesting an alternate resistance mechanism. 30463788 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE Osimertinib was approved by the US Food & Drug Administration in November 2015 for patients whose tumors exhibited T790M mutation and for those with progressive disease on other EGFR TKIs. 28367058 2017
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation phenotype BEFREE Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease. 29624648 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 GeneticVariation phenotype BEFREE Adjusted response rates were (N, %): Complete Response (CR) (69/3153, 2.19%), Partial Response (PR) (596/3153, 18.90%), Stable Disease (SD) (632/2463, 25.66%) and PD (1027/2463, 41.70%); and CR (16/2955, 0.54%), PR (263/2955, 8.90%), SD (835/2269, 36.80%) and PD (834/2269, 36.76%) with anti-PD1/PD-L1 mAbs and SOC, respectively. 29492229 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation phenotype BEFREE Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG. 28727518 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 GeneticVariation phenotype BEFREE Traditional RECIST criteria are not suited for proper assessment of response to PD-(L)1 inhibitors; and more tailored criteria (e.g. immune-related response criteria) should be employed for patients treated with PD-(L)1 inhibitors; moreover in patients with an evidence of disease progression on initial disease evaluation, treatment should not be stopped except after confirmation of progressive disease with a second evaluation at least 4 weeks later. 28971749 2017
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation phenotype BEFREE In patients with clinical benefit (progressive disease after 8 weeks), ctDNA testing revealed previously undetected mutations in RAS/BRAF (71%) and EGFR (47%), which often emerged polyclonally. 31350822 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation phenotype BEFREE TP53 mutations were associated with chemoresistance, defined as progressive disease on therapy (p = 0.0358; p = 0.0136 for mutations affecting p53 loop domains L2/L3). 18725978 2008
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation phenotype BEFREE Moreover, early adaptive responses limit the initial efficacy of BRAF inhibition, leading mostly to incomplete responses that may favor the selection of a sub-population of resistant clones and the acquisition of alterations that cause tumor regrowth and progressive disease. 25344914 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE NSCLC patients harboring EGFR T790 M mutations who experienced progressive disease after first EGFR-TKI treatment and started osimertinib treatment between April 2016 and August 2018 were retrospectively screened. 31183631 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE EGFR mutation type, sites of LT, and time from first progressive disease (PD) to LT were prognostic of OS after LT. 28465010 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation phenotype BEFREE In two patients with K-RAS mutations pretreatment, posttreatment plasmas were evaluated: a patient with clinical progressive disease retained the mutant DNA, while in a patient with a complete response (CR), the K-RAS mutation was no longer detectable. 15251940 2004
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE In a subset of patients, we further showed that reappearance of EGFR mutations could be detected in plasma up to 5 months ahead of progressive disease (PD), suggesting an early detection of drug resistance. 28969034 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE High EGFR gene copy number was identified in two patients experiencing partial response or progressive disease. 16575012 2006
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation phenotype BEFREE The absence of statistically significant correlations between p53 gene mutation and progressive disease, however, does not deny its putative relevance in early phases of tumor development. 9250931 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation phenotype BEFREE Patients with complete or partial remission were compared with those with stable or progressive disease with respect to TP53 genotype and overall survival. 10096970 1999
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation phenotype BEFREE KRAS mutations were detected in two of 49 (4%) patients, both of whom had rapid progressive disease. 19884861 2009
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE Adult patients (age > or = 18 years), with non squamous EGFR mutation, treated with first line palliative therapy, with non progressive disease post 4-6 cycles of pemetrexed-carboplatin were randomized. 31695838 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation phenotype BEFREE Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumours containing wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response). 16880785 2006
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation phenotype BEFREE Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease). 27105424 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE Patients received the second epidermal growth factor receptor-tyrosine kinase inhibitor after experiencing an adverse event or progressive disease on the first epidermal growth factor receptor-tyrosine kinase inhibitor. 22457323 2012
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE We compared amphiregulin expression using immunohistochemistry in EGFR wild-type NSCLC patients (n=24) that developed either stable or progressive disease following erlotinib or gefitinib treatment. 18980991 2008
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE We analyzed gefitinib responders with activating EGFR mutations who developed progressive disease (PD) during the course of therapy. 23261231 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation phenotype BEFREE However, the levels of the EGFR exon 19 deletion driver mutation and the T790M resistance mutation in the circulating tumor DNA continued to rise and the patient died from progressive disease 6 weeks after commencement of combination therapy. 28843359 2017